Health Strategies Group Key Finding #1 12/2/2018 Health Strategies Group Author/Artist Evolving Market Dynamics Will Continue to Influence and Limit Access to Branded MS Drugs by 2019 Availability of new brands and potential entrance of multisource generics will compel stakeholders to intensify management tactics to further narrow preferred branded MS drugs. Biopharmaceutical companies that support stakeholder objectives of achieving high-quality, cost- effective long-term care for MS patients will benefit from improved relations and likely sustain optimal access for their brands. To request slides info@healthstrategies.com